eligibility_summary
Eligibility: Adults ≥18 with histologically confirmed genitourinary cancer (kidney, renal pelvis/ureter, bladder, prostate, testis/germ cell incl. extragonadal, urethra, penis, seminal vesicles) treated at the participating center. Treatment must start after Spanish NHS funding approval/publication (post Jan 1, 2023). Consent required unless exempt. Exclude: prior treatment at another center, ineligible, or explicit objection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
PRINCIS is a Spanish multicenter, non-interventional registry evaluating real‑world effectiveness of newly funded genitourinary cancer drugs. Interventions and mechanisms: 1) Darolutamide (small‑molecule, non‑steroidal androgen receptor antagonist) used with androgen deprivation therapy (lowers androgen production) and docetaxel (microtubule‑stabilizing cytotoxic). Targets: androgen receptor signaling in prostate cancer cells, microtubules in proliferating tumor cells. 2) Nivolumab (IgG4 monoclonal antibody immune checkpoint inhibitor) blocks PD‑1 on T cells to restore antitumor activity. Targets: PD‑1/PD‑L1 axis on T cells and tumor/immune cells in urothelial carcinoma. 3) Enfortumab vedotin (antibody–drug conjugate) binds Nectin‑4 on urothelial tumor cells, delivering MMAE, a microtubule‑disrupting payload that induces cell death. The study does not assign treatments, it observes outcomes in routine practice.